

SUBJECT INDEX TO VOLUME 1

- Acute lung injury (ALI) 159
 adult studies of 162
 exogenous surfactant therapy for 159,161
 in children 161
 paediatric studies of 162
 routes of surfactant administration in 164
 surfactant system in 161
- Acute respiratory distress syndrome (ARDS) 159
 adult studies of 162
 exogenous surfactant therapy for 159,161
 in children 161
 paediatric studies of 162
 routes of surfactant administration in 164
- Adverse drug reactions 169,289
 IMMP methodology for 170
 New Zealand intensive medicines
 monitoring program for 169
 unrecognized signals of 169
- Anaphylactic reactions 244
 drug induced 244
- Antidepressants 81
 adverse effects of 81
 suicide/self harm associated with use of 81
- Antiepileptic drug 289
 induced hypersensitivity syndrome reactions 289
- Antimalarial drug 1
 halofantrine as 8
 in pregnancy 1
 primaquine as 8
 tetracycline/doxycycline as 8
- Aspirin 282
 in surgery 282
- Atypical antipsychotic agents 227
 conventional antipsychotics for 227
 in schizoaffective disorders of elderly 227
 in treatment of schizophrenia 227
- Bipolar disorder 25,307
 adolescents with 307
 anticonvulsants for 27,311
 antidepressants for 29
 antipsychotics for 312
 atypical antipsychotics for 28
 benzodiazepines for 29
 carbamazepine for 27
 children with 307
 conventional mood-stabilizers for 25
 drug safety in 307
 economic burden of 307
 epidemiology of 307
 etiology/pathophysiology of 308
 in pregnancy 25
 in puerperium 25
 issues of bipolar management 313
 lithium for 25
 management of 308
 medications for 29
 non-pharmacologic therapy for 309
 oxcarbazepine for 27
 pharmacological intervention for 309
 pharmacological treatments for 25,30,315
 safety of drugs used to treat 25,310
 valproate for 25
- Botulinum toxin 271
 advantages/disadvantages of 273
 adverse effects of 271-273
 anticholinergic adverse effects of 274
 clinical use of 272
 dose-adverse effects relationship of 274
 fatality associated with treatment with 275
 immune-mediated/idiosyncratic adverse effects
 of 275
 intramuscular 271
 management of adverse effects of 277
 mode of action of 271
 preparations of 272
- Cancer 107
 5-fluorouracil in 111
 host pharmacogenetics in treatment of 107
 irinotecan in 111
 platinum agents in 112
 thiopurines in 110
- Chemotherapy 35
- Chemotherapy agents 243
 hypersensitivity reactions to 243
 rapid desensitization with 243
- Ciclesonide 265
 hypothalamic pituitary-adrenal-axis function
 in adults 266
 lower leg growth velocity in children by 267
 oropharyngeal adverse events in adults 268
 oropharyngeal adverse events in children 269
 oropharyngeal safety profile of 268
 systemic/oropharyngeal safety profile of 265
- Cilostazol 285
 in surgery 285
- Clopidogrel 283
 in surgery 283
- Cyclo-oxygenase-2 (COX-2) inhibitors 175
 signals identified with 175
- Dipyridamole 284
 in surgery 284
- Endogenous surfactant system 159
 surfactant protein A in 160
 surfactant protein B in 160

- surfactant protein C in160
 surfactant protein D in160
 Erythema nodosum259
 Etanercept262
 skin lesions associated with262
 Excessive hair growth303

 Growth factors35
 in prevention/treatment of chemotherapy-
 induced peripheral neurotoxicity35

 Hair disorders301
 by antineoplastic agents301
 by antiretrovirals301
 by interferons301
 by minoxidil301
 by oral contraceptives302
 by psychotropics303
 by radiation303
 by retinoids303
 by retinol303
 drug-induced301
 reversible hair loss in301
 Headache43
 as adverse reaction to drugs43
 by antihistamines47
 by anti-infective agents46
 by anti-inflammatory agents47
 by cardiovascular drugs44
 by central nervous system (CNS) drugs50
 by drug used in treatment of asthma47
 by gastrointestinal agents48
 by hormonal agents49
 by immunomodulatory agents47
 by immunosuppressant47
 by miscellaneous agents51
 HIV107
 antiretroviral agents in107
 host pharmacogenetics in treatment of107
 hypersensitivity reactions in107
 γ -Hydroxybutyrate (GHB)99
 abuse of100
 clinical development of99
 clinical use of100
 in risk management program102
 neurophysiology of99
 post-marketing surveillance of104
 safety data of102
 Hypersensitivity syndrome reactions291
 by carbamazepine292
 by ethosuximide294
 by felbamate294
 by gabapentin294
 by lamotrigine293
 by levetiracetam294
 by oxcarbazepine294
 by phenobarbital293
 by phenytoin292
 by tiagabine294
 by topiramate294
 by valproic acid293
 by vigabatrin295
 by zonisamide295
 lymphocyte toxicity assay of295
 Hypnotics63
 and driving safety63
 meta-analysis of randomized controlled
 trials of63

 Influenza118
 Inhaled corticosteroids265
 hypothalamic pituitary-adrenal-axis
 function of265
 systemic exposure to265
 Inhaled corticosteroids268
 effect of local deposition of268
 Inhaled insulin151
 devices for152
 efficacy data of154
 novel/non-invasive way for administration of151
 patient satisfaction by157
 pharmacodynamic/pharmacokinetic
 profiles of153
 safety data of156
 Interferon143
 clinical recommendations of146
 psychiatric side effects of143
 Interferon alpha145
 delirium by145
 depression by145
 in cancer chemotherapy145
 in hepatitis C145
 mania by146
 non-specific symptoms by146
 Interferon beta144
 delirium by144
 depression by144
 in MS144
 non-specific symptoms by145

 Leukemia inhibitory factory (LIF)37

 Malignant glioma205
 clinical experiences with205
 drug interactions of219
 in infections212
 myelosuppression by205
 non-haematologic toxicity of212
 paediatric administration of220
 safety of temozolamide in patients with205

Measles	118	role in fracture healing	198
Medicinal products	121	safety/efficacy of	189,198
implications for	121	sequential treatment with	196
safe/effective use of	121	tolerability of	198
Medicines	121	Parkinson's disease (PD)	223
risks/benefits of	121	NSAID for	223
Micro/array studies	135	Permanent alopecia	303
sources of false positives in	135	Pharmacogenetics	113
stability/reproducibility in	138	in clinical practice	113
typical statistical methods for pharmacogenomic type	136	Pharmacogenomic biomarker	135
Nephrotoxicity	184	reducing false positive findings in	135
role of apoptosis	184	statistical analysis of	135
role of TGF- β 1	184	studies using high-throughput technologies	135
Neurotoxicity	35	Pharmacovigilance	127
BDNF in	37	advances in post-marketing strategies of	130
ciliary neurotrophic factor (CNTF) for	39	advances in pre-marketing strategies of	128
erythropoietin for	39	benefit-risk management plans (BRMPs) in	132
glial cell line-derived neurotrophic factor (GDNF) for	39	paradigms in	127
insulin-like growth factor-1 (IGF-1) for	39	specifications of	132
neurotrophic agents for	39	Plasmid/liposome	253
neurotrophin gene therapy for	38	in clinical gene therapy	253
NGF in	37	Polio	117
NGF-modulating/NGF-mimicking drugs for	38	in Nigeria	117
NT-3 in	37	Postmenopausal osteoporosis	87
Neurotransmitter uptake inhibitors	73	combined treatment with vitamin K2/ bisphosphonates in	93
off-label use in urology	78	combined treatment with vitamin K2/ raloxifene in	95
on-label use in urology	77	combined treatment with vitamin K2/vitamin D ₃ in	92
Neurotrophins	37	role of vitamin K ₂ in	87
Nocturnal enuresis	77	treatment of	87
TCA in	77	Pregnancy	1,17
Non steroidal anti-inflammatory drugs (NSAIDs)	223	amodiaquine in	2
Oral antiplatelet agents	281	antimalarial drugs not used in	8
in bleeding risk	281	artemisinin derivatives in	6
in cardiovascular surgery	281	atovaquone-proguanil in	7
Parathyroid hormone (PTH)	189	azithromycin in	3
alendronate in combination with	194	chloroquine in	1
animal studies of	192	dapsone in combination with chlorproguanil in	5
as biological response modifier	189	lumefantrine in	7
biology of	190	mefloquine in	5
calcitonin in combination with	196	quinine in	2
concomitant treatments with	194	risk of long-term effects in	19
effect on bone regeneration	189	risk of neonatal symptoms in	18
efficacy in human trials	193	risk of teratogenesis in	18
hormone replacement therapy (HRT)	196	risk of untreated depression in	14
in glucocorticoid-induced osteoporosis (GIO)	197	safety of selective serotonin reuptake inhibitors in	17
in men with osteoporosis	197	Premature ejaculation	78
in postmenopausal osteoporosis	193	SSRI/TCA in	78
mechanism of action of	190	Rapid desensitization	244
preclinical effects of	198	cellular/molecular targets of	244
		for biological agents/monoclonal antibodies	248
		for hypersensitivity reactions to platinum	246

- for hypersensitivity reactions to taxenes245
- in cancer progression248
- to chemotherapy drugs including taxenes/
platin245
- Retrograde ejaculation78
- TCA in79
- Rheumatoid arthritis259
- anti-TNF α drug for259
- dermatological reactions in259
- injection site haematoma in260
- treated with etanercept259
- Risperidone176
- epistaxis by176
- Schizoaffective disorder227
- aripiprazole for238
- clozapine for229
- olanzapine for234
- quetiapine for235
- risperidone for231
- treatment challenges for227
- ziprasidone for237
- Schizophrenia227
- aripiprazole for238
- clozapine for229
- olanzapine for234
- quetiapine for235
- risperidone for231
- treatment challenges for227
- ziprasidone for237
- Selective serotonin reuptake inhibitors (SSRIs)17
- Sirolimus (SRL)179
- associated proteinuria181,185
- based early graft nephrotoxicity179
- clinical/experimental data of179
- enhances calcineurin inhibitors nephrotoxicity180
- experimental data of183
- induced acute renal failure182
- induced thrombotic microangiopathy182
- pharmacokinetic interaction of183
- prolongs recovery from delayed graft function181
- Sodium oxybate oral solution101
- clinical development of101
- Sumatriptan175
- pain activation with175
- Ticlopidine283
- in surgery283
- Urologic disease73
- tolerability of amine uptake inhibitors in73
- Vaccine117
- safety of117
- Virus vectors253
- in clinical gene therapy253
- Vitamin K87
- deficiency of89
- effect on bone metabolism89
- effect on postmenopausal osteoporosis89
- in combination with other agents on
 postmenopausal osteoporosis91
- role in fracture risk89